Amantadine Therapy for Cognitive Impairment in Long COVID

NCT ID: NCT06055244

Last Updated: 2026-01-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-07
• Study Completion Date: 2025-12-29

Brief Summary

This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.

Detailed Description

This study will enroll 60 subjects with Long COVID and cognitive symptoms such as problems with memory, concentration, speech and attention, and "brain fog." Subjects will be assigned randomly to two groups. One group will be treated with amantadine, the other group will receive placebo. The study will last 4 months. During that time, subjects will be assessed at regular intervals with symptom questionnaires, cognitive tests, and lab measurements.

Conditions

Long COVID; Post-COVID19 Condition; Post-Acute COVID19 Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Amantadine

Subjects will be treated with amantadine.

Group Type: EXPERIMENTAL

Amantadine

Intervention Type: DRUG

Subjects will be give amantadine 100 mg twice daily.

Placebo

Subjected received placebo identical to amantadine in appearance.

Group Type: PLACEBO_COMPARATOR

Amantadine

Intervention Type: DRUG

Subjects will be give amantadine 100 mg twice daily.

Interventions

Amantadine

Subjects will be give amantadine 100 mg twice daily.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 18 years of age and above at the signing of informed consent

2. Had a positive laboratory or home test for COVID19 within one year prior to signing of informed consent, with subsequent symptoms meeting criteria for PASC.

3. Subjective Cognitive impairment associated with PASC

4. Cognitive symptoms will be formally assessed at a pre-enrollment visit using the PROMIS Cognitive Function Questionnaire (CGQ) and the PROMIS Cognitive Abilities subset (CAS), which are validated patient-reported measures of subjective cognitive functioning. Potential participants must have a cumulative score less than 60 (indicating at least mild subjective cognitive dysfunction) to be eligible.

5. Is willing and able to comply with study visits and study-related procedures/assessments.

6. Is able to provide informed consent to participate in the study 5.

7. Is not currently taking a medication with adverse interactions with amantadine. (Table 2)

8. If the participant is of child bearing potential, , is not pregnant at enrollment based on negative urine pregnancy test.

9. If the participant is of child-bearing potential, is consistently using one or more forms of prescribed birth control, such as an oral contraceptive, intrauterine device or a long-acting reversible contraceptive.

10. Is not breastfeeding.

11. Is willing to abstain from alcohol use for the duration of the study.

12. Endorses self-reported cognitive impairment on the PROMIS CF[40].

13. Does not have any other contraindications to amantadine use as noted in section 6 below or as identified by the study clinician investigators.

Exclusion Criteria

1. At risk for complications of study drug with conditions such as:

• Lifetime history of compulsive or impulsive behavior: Compulsive gambling, hypersexuality, binge eating; suicidality.
• Underweight, malnourished at time of enrollment.
• History of restrictive eating disorder within 3 months prior to consent.
• Lifetime history of heart failure or diagnosed cardiac arrhythmia.
• Untreated angle closure glaucoma at time of enrollment.
• Lifetime history of psychosis or psychotic disorder.
• Lifetime history of seizure disorder.
• Known allergy to amantadine.
• History of binge drinking, heavy alcohol use, or alcohol use disorder as defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA)[54] and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)[55].
• Use of kava-kava within 3 months prior to consent.
• Breastfeeding at screening or expected to be breastfeeding during study period.
• Pregnant at time of screening or expecting to become pregnant during the study period.

2. Is taking a medication that adversely interacts with amantadine (see Table 2)

3. Has any physical examination findings, and/or history of any illness, concomitant medications or recent live vaccines that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by their participation in the study.

4. Prior diagnosis of dementia, neurodegenerative disorder, multiple sclerosis or other autoimmune neurologic disorder, or cognitive impairment.

5. Enrolled in any other research study involving intervention for PASC.

6. If the individual is of child-bearing potential, is not consistently using one or more forms of prescribed birth control.

7. Is not willing to abstain from alcohol for the duration of the study.

8. Is not willing and able to adhere to study visits and study-related procedures/assessments.

9. Is not able to provide informed consent to participate in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ohio State University

OTHER

Sponsor Role: lead

Responsible Party

Andrew Schamess

Associate Professor - Clinical

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Andrew I Schamess, MD

Role: PRINCIPAL_INVESTIGATOR

Ohio State University

Locations

The Ohio State University Medical Center

Columbus, Ohio, United States

Countries

United States

Other Identifiers

GF317855

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2023H0268

Identifier Type: -

Identifier Source: org_study_id